Margareth Ribe

Margareth Ribe

Auto-generated profile, based on publicly available information

Margareth Ribe

ProCardio Center for Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet , PO Box 4950 Nydalen, 0424 Oslo , Norway

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
EAEivind Westrum Aabel
Eivind Westrum Aabel
MCMonica Chivulescu
Monica Chivulescu
ØLØyvind H Lie
Øyvind H Lie
EHEinar Hopp
Einar Hopp
EGErik Gjertsen
Erik Gjertsen
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
Arrhythmic mitral valve syndrome is linked to life-threatening ventricular arrhythmias. The incidence, morphology and methods for risk stratification are not well known. This prospective study aimed to describe the incidence and the morphology of ventricular arrhythmia and propose risk stratification in patients with arrhythmic mitral valve syndrome. Arrhythmic mitral valve syndrome patients were monitored for ventricular tachyarrhythmias by implantable loop recorders (ILR) and secondary preventive implantable cardioverter-defibrillators (ICD). Severe ventricular arrhythmias included ventricular fibrillation, appropriate or aborted ICD therapy, sustained ventricular tachycardia and non-sustained ventricular tachycardia with symptoms of hemodynamic instability. During 3.1 years of follow-up, severe ventricular arrhythmia was recorded in seven (12%) of 60 patients implanted with ILR [first event incidence rate 4% per person-year, 95% confidence interval (CI) 2–9] and in four (20%) of 20 patients with ICD (re-event incidence rate 8% per person-year, 95% CI 3–21). In the ILR group, severe ventricular arrhythmia was associated with frequent premature ventricular complexes, more non-sustained ventricular tachycardias, greater left ventricular diameter and greater posterolateral mitral annular disjunction distance (all P < 0.02). The yearly incidence of ventricular arrhythmia was high in arrhythmic mitral valve syndrome patients without previous severe arrhythmias using continuous heart rhythm monitoring. The incidence was even higher in patients with secondary preventive ICD. Frequent premature ventricular complexes, non-sustained ventricular tachycardias, greater left ventricular diameter and greater posterolateral mitral annular disjunction distance were predictors of first severe arrhythmic event. We included 80 patients with arrhythmic mitral valve syndrome followed for 3.1 years; 60 were implanted with a loop recorder (ILR) and 20 had prior implantable cardioverter defibrillator (ICD). Severe ventricular arrhythmia occurred in seven patients (12%) in the ILR-group and four (20%) in the ICD-group. Servier Medical Art. LV = left ventricle, MR = mitral regurgitation, MVP = mitral valve prolapse, NSVT = non-sustained ventricular tachycardia, PVC = premature ventricular complex, VT = ventricular tachycardia.

6 April 2021 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
ESEystein T Skjølsvik
Eystein T Skjølsvik
ØLØyvind Haugen Lie
Øyvind Haugen Lie
MCMonica Chivulescu
Monica Chivulescu
MRMargareth Ribe
Margareth Ribe
ACAnna Isotta Castrini
Anna Isotta Castrini
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
Aims: We aimed to study the progression of cardiac dysfunction in patients with lamin A/C mutations and explore markers of adverse cardiac outcome. Methods and results: We followed consecutive lamin A/C genotype-positive patients divided into tertiles according to age. Patients underwent repeated clinical examinations, electrocardiograms (ECGs), and echocardiograms. We followed left ventricular (LV) and right ventricular (RV) size and function, and the severity atrioventricular-valve regurgitations. Outcome was death, LVAD implant, or cardiac transplantation. We included 101 patients [age 44 (29–54) years, 39% probands, 50% female]. We analysed 576 echocardiograms and 258 ECGs during a follow-up of 4.9 (interquartile range 2.5–8.2) years. The PR-interval increased at young age from 204 ± 73 to 212 ± 69 ms (P < 0.001), LV ejection fraction (LVEF) declined from middle age from 50 ± 12% to 47 ± 13% (P < 0.001), while LV volumes remained unchanged. RV function and tricuspid regurgitation worsened from middle age with accelerating rates. Progression of RV dysfunction [odds ratio (OR) 1.3, 95% confidence interval (CI) (1.03–1.65), P = 0.03] and tricuspid regurgitation [OR 4.9, 95% CI (1.64–14.9), P = 0.004] were associated with outcome when adjusted for age, sex, comorbidities, LVEF, and New York Heart Association functional class. Conclusion: In patients with lamin A/C genotype, electrical disease started at young age. From middle age, LV function deteriorated progressively, while LV size remained unchanged. Worsening of RV function and tricuspid regurgitation accelerated in older age and were associated with outcome. Our systematic map on cardiac deterioration may help optimal monitoring and prognostication in lamin A/C disease.

10 November 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
CRChristine Rootwelt-Norberg
Christine Rootwelt-Norberg
ESEystein T Skjølsvik
Eystein T Skjølsvik
MCMonica Chivulescu
Monica Chivulescu
MBMartin P Bogsrud
Martin P Bogsrud
MRMargareth P Ribe
Margareth P Ribe
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
Cardiac disease progression prior to first ventricular arrhythmia (VA) in LMNA genotype–positive patients is not described. We performed a primary prevention cohort study, including consecutive LMNA genotype–positive patients from our centre. Patients underwent repeated clinical, electrocardiographic, and echocardiographic examinations. Electrocardiographic and echocardiographic disease progression as a predictor of first-time VA was evaluated by generalized estimation equation analyses. Threshold values at transition to an arrhythmic phenotype were assessed by threshold regression analyses. We included 94 LMNA genotype–positive patients without previous VA (age 38 ± 15 years, 32% probands, 53% females). Nineteen (20%) patients experienced VA during 4.6 (interquartile range 2.1–7.3) years follow up, at mean age 50 ± 11 years. We analysed 536 echocardiographic and 261 electrocardiogram examinations. Individual patient disease progression was associated with VA [left ventricular ejection fraction (LVEF) odds ratio (OR) 1.4, 95% confidence interval (CI) 1.2–1.6 per 5% reduction, left ventricular end-diastolic volume index (LVEDVi) OR 1.2 (95% CI 1.1–1.3) per 5 mL/m2 increase, PR interval OR 1.2 (95% CI 1.1–1.4) per 10 ms increase]. Threshold values for transition to an arrhythmic phenotype were LVEF 44%, LVEDVi 77 mL/m2, and PR interval 280 ms. Incidence of first-time VA was 20% during 4.6 years follow up in LMNA genotype–positive patients. Individual patient disease progression by ECG and echocardiography were strong predictors of VA, indicating that disease progression rate may have additional value to absolute measurements when considering primary preventive ICD. Threshold values of LVEF 77 mL/m2, and PR interval >280 ms indicated transition to a more arrhythmogenic phenotype. In a primary prevention cohort of 94 LMNA genotype–positive patients without VA at baseline, VA incidence was as high as 20% after 4.6 years follow up. Individual patient disease progression by ECG and echocardiography was a strong predictor of subsequent VA, suggesting additional value to the previously described risk factors in current guidelines for primary preventive ICD implantation. Threshold values of LVEF 280 ms indicated transition to a more arrhythmogenic phenotype. ECG, electrocardiogram; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; VA, ventricular arrhythmia.

1 October 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EAE Aabel
E Aabel
MCM Chivulescu
M Chivulescu
ØLØ H Lie
Ø H Lie
CRC Rootwelt-Norberg
C Rootwelt-Norberg
MRM Ribe
M Ribe
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
Background: Arrhythmic mitral valve syndrome is linked to life-threatening ventricular arrhythmias, but the incidence and methods for risk stratification of ventricular arrhythmias are not well known. Purpose: In this prospective study, we aimed to describe the incidence of ventricular arrhythmias by use of continuous rhythm monitoring and propose risk stratification in patients with arrhythmic mitral valve syndrome. Methods: We included consecutive patients with arrhythmic mitral valve prolapse, defined as mitral valve prolapse and/or mitral annulus disjunction (MAD) with arrhythmic symptoms or documented complex premature ventricular complexes (PVC). We implanted loop recorders (ILR) in patients with arrhythmic mitral valve syndrome with no previous severe ventricular arrhythmias and all were followed by remote monitoring. We monitored for non-sustained ventricular tachycardias (NSVT) and severe ventricular arrhythmia, defined as aborted cardiac arrest, sustained ventricular tachycardia and NSVT with syncope/presyncope. At baseline, patients underwent echocardiography, 24-hour Holter monitoring, stress ECG and cardiac magnetic resonance imaging. Results: We included 60 patients (73% female, 49 years [interquartile range [IQR] 37–60]). At baseline, median PVC burden was 232 per 24-hours (IQR 33–1329), and 8 (13%) patients had NSVT by Holter monitoring or stress ECG. During 3.0±0.5 years of follow-up, severe ventricular arrhythmia occurred in 7 (12%) patients (1 aborted cardiac arrest, 6 NSVT with syncope/pre-syncope). Annual incidence rate of severe events was 4% per person-year (95% confidence interval [CI] 2–9)). Predictors of severe ventricular arrhythmia were frequent PVCs (6683 PVCs per 24h [IQR 612–10861] vs. 154 PVCs per 24h [IQR 25–562], p=0.01), more NSVTs by ILR (4 NSVTs [IQR 2–7] vs. 0 NSVTs [0–1], p<0.001), greater left ventricular diameter (57±6 mm vs. 51±6 mm, p=0.01) and greater posterolateral MAD distance (9 mm [IQR 8–12] vs. 4 mm [IQR 0–6], p=0.02). Adjustment for age and sex did not change significant risk markers (all p<0.02). During follow-up 102 NSVTs were recorded in 24 (40%) patients. In multivariate Poisson regression adjusting for age, mitral regurgitation grade and bileaflet prolapse, predictors of high NSVT burden were frequent PVCs (incidence rate ratio [IRR] 1.14 [95% CI 1.04–1.27], p=0.01), PVCs from inferior left ventricle (IRR 5.19 [95% CI 2.80–9.63], p<0.001) and late gadolinium enhancement (IRR 3.16 [95% CI 1.68–5.97], p<0.001). Conclusion: Yearly incidence of first severe ventricular arrhythmia was 4% in patients with arrhythmic mitral valve syndrome, emphasizing the high risk of life-threatening events in these patients. Frequent PVCs, NSVTs, greater left ventricular diameter and greater posterolateral MAD distance were predictors of first severe ventricular arrhythmia and should be used in risk stratification. Funding Acknowledgement: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): This study was supported by a public grant from the Norwegian Research Council (#288438 and #309762), Precision Health Center for optimized cardiac care (ProCardio).